FQFan Qiao

Fan Qiao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fan Qiao has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Chao Ye

    Department of Cardiovascular Surgery, Changhai hospital affiliated to the Naval Medical University, Shanghai, 200433, China

    1 shared publication
  • Fanglin Lu

    Department of Cardiovascular Surgery, Shanghai General Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China

    1 shared publication
  • Fanglin Lu

    Department of Cardiovascular Surgery, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China

    1 shared publication
  • Fei Chen

    Laboratory of Cardiac Structure and Function , Institute of Cardiovascular Diseases , West China Hospital , Sichuan University , Chengdu , Sichuan, China , scu.edu.cn

    1 shared publication
  • Hongjie Xu

    National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, 210002, China

    1 shared publication
  • Jiajun Pan

    Department of Cardiovascular Surgery, Changhai hospital affiliated to the Naval Medical University, Shanghai, 200433, China

    1 shared publication

Latest Publications

  • Transjugular Transcatheter Tricuspid Valve Implantation of Coronary Stent System for Creating a Rat Tricuspid Regurgitation Model

    by Xiaoping Ning, Hongjie Xu, Quangong Zhao, Jiajun Pan, Xiaohong Liu, Jingyi Cao, Qin Li, Sufan Ding, Chao Ye, Keng Zhong, et al.

    We aimed to establish a rat TR model to further investigate the mechanisms of right heart remodeling and organ damage induced by TR. Intervention group rats (n = 6) underwent coronary stent system implantation via transjugular approach. The control group (n = 6) underwent the same procedure, except for coronary stent implantation. All rats survived at 8 weeks follow-up postoperatively. TR occurred immediately after the implantation of coronary stent in the intervention group. The right ventricular fractional area change (FAC) decreased by 33.9% compared with baseline from 0.59 ± 0.11% to 0.39 ± 0.10% (P = 0.005) and the tricuspid annular plane systolic excursion (TAPSE) decreased by 36.8% from 2.42 ± 0.31 mm to 1.53 ± 0.45 mm at 8 weeks (P < 0.001). This animal model would be suitable to further investigate the mechanisms of right ventricular remodeling and other organ damage associated with TR.

  • Open Access

    Transcatheter Tricuspid Valve Replacement in Patients After Prior Left‐Sided Valve Surgery: A Multicenter Retrospective Analysis

    by Tianyuan Xiong, Yi Zhang, Fan Qiao, Yuan Feng, Zhengang Zhao, Xin Wei, Xi Li, Fei Chen, Xingyu Ji, Junbo Ge, et al.

    Background: Functional tricuspid regurgitation (TR) after previous left‐sided valve surgery (LSVS) represents a significant proportion of all isolated TR cases; tricuspid valve reoperation in such patients, often in the advanced stage of disease, is historically regarded as high‐risk. Percutaneous transcatheter–based therapies for TR emerge as a potential solution. We sought to verify the performance of the LuX‐Valve Plus system in patients with a history of LSVS. Methods: A post hoc analysis of patients enrolled in the first‐in‐man and confirmatory study and an investigator‐initiated trial of the LuX‐Valve Plus system was conducted. Multiple endpoints, including mortality, valve performance, and functional status, were compared between patients with or without a history of LSVS. Propensity score matching (PSM) was used to minimize baseline differences between groups. Results: The study included 153 patients, with 56 patients having prior LSVS. After PSM, there were a total of 46 matched pairs. All‐cause mortality at 6 months was similar between groups (2.38% vs. 0%, respectively). Less‐than‐moderate paravalvular leakage and central TR were consistently observed in approximately 85% and 95% of patients through 6 months. Patients after prior LSVS achieved similar functional outcome in terms of the proportion of patients in NYHA Class I–II at 6 months (81.25% vs. 95.83%, p = 0.221). The Kansas City Cardiomyopathy Questionnaire score improved significantly after the procedure. Conclusions: In this small‐scale study, transcatheter implantation of the LuX‐Valve Plus for TR appeared to be safe and effective in patients with a history of LSVS, showing lower short‐term mortality and a degree of TR correction comparable to surgical outcomes.